IP Library Granted Patent US 8,476,308
Granted Patent B2
US 8,476,308 · App. 13/645,287 · Granted Jul 2, 2013

GPR120 receptor agonists and uses thereof

Inventors: Dong Fang Shi (Fremont, CA); Jiangao Song (Sunnyvale, CA); Jingyuan Ma (Sunnyvale, CA); Aaron Novack (San Jose, CA); Phuongly Pham (Hayward, CA); Imad Fayek Nashashibi (San Jose, CA); Christopher J. Rabbat (Calabasas, CA); Xin Chen (San Ramon, CA)
Assignee: Metabolex, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,476,308
App. No.
13/645,287
Granted
Jul 2, 2013
Kind
B2
Abstract

GPR120 agonists are provided. These compounds are useful for the treatment of metabolic diseases, including Type II diabetes and diseases associated with poor glycemic control.

Claims (10)

1. A compound selected from the group consisting of:

3-(4-((5-fluoro-1-(methoxycarbonyl)-2,2-dimethylindolin-7-yl)methoxy)-2,3-dimethylphenyl)propanoic acid;

3-(4-((5-fluoro-2,2-dimethylindolin-7-yl)methoxy)-2,3-dimethylphenyl)propanoic acid; and

3-(4-((5-fluoro-1,2,2-trimethylindolin-7-yl)methoxy)-2,3-dimethylphenyl)propanoic acid,

or a pharmaceutically acceptable salt thereof.

2. A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

3. A method of treating a disease or condition selected from the group consisting of Type I diabetes, Type II diabetes and metabolic syndrome, said method comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of claim 1 .

4. The method of claim 3 , wherein said disease is Type II diabetes.

5. A method of lowering blood glucose in a mammal, said method comprising administering a therapeutically effective amount of a compound of claim 1 to a mammal in need of such treatment.

6. The method of claim 5 , wherein said mammal is a human.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Aug 7, 2015
From: SILICON VALLEY BANK; OXFORD FINANCE LLC
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 036307/0406 →
SECURITY AGREEMENT Recorded Nov 22, 2013
From: CYMABAY THERAPEUTICS, INC.
To: SILICON VALLEY BANK; OXFORD FINANCE LLC
Reel/Frame 031710/0508 →
CHANGE OF NAME Recorded Nov 6, 2013
From: METABOLEX, INC.
To: CYMABAY THERAPEUTICS, INC.
Reel/Frame 031589/0193 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2012
From: SHI, DONG FANG; SONG, JIANGAO; MA, JINGYUAN; NOVACK, AARON; PHAM, PHUONGLY; NASHASHIBI, IMAD FAYEK; RABBAT, CHRISTOPHER J.; CHEN, XIN
To: METABOLEX, INC.
Reel/Frame 029523/0315 →
Continuity (2)
Division 12817116 · Jun 16, 2010
Related Publication 20130109734A1 · May 2, 2013